Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients

Cancer

Volumn 104, Issue 11, 2005, Pages 2437-2441

  Marchi, Enrica ^a   Alinari, Lapo ^a   Tani, Monica ^a   Stefoni, Vittorio ^a   Pimpinelli, Nicola ^b   Berti, Emilio ^c   Pagano, Livio ^d   Bernengo, Maria Grazia ^e   Zaja, Francesco ^f   Rupoli, Serena ^g   Pileri, Stefano ^a   Baccarani, Michele ^a   Zinzani, Pier Luigi ^a,h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cutaneous T cell lymphoma (CTCL); Gemcitabine; Untreated patients

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MALE; MYCOSIS FUNGOIDES; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPIOID INDUCED EMESIS; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEZARY SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 28044451294     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21449     Document Type: Article

References (28)

1. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Russell-Jones R. World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. J Am Acad Dermatol 2003;48:93-102.
4. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3:193-215.
5. Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clin Dermatol. 2004;22:197-208.
6. 389-Interleukin 2 (ON-TAK) in the management of cutaneuous T-cell lymphoma. Curr Pract Med. 1999;2:167-170.
7. Rook AH, Kubin M, Fox FE, et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann N Y Acad Sci. 1996;795:310-318.
8. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920-2924.
9. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003:98:993-1001.
10. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol. 2000;42:40-46.
11. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12:2588-2593.
12. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603-2606.
13. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:1351-1353.
14. Sallah S, Wehbie R, Lepera P, Sallah W, Bobzien W. The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Br J Haematol. 1999;104:163-165.
15. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615-2619.
16. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000;85:926-929.
17. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3786-3792.
18. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol. 2001;113:772-778.
19. Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 1988;61:2310-2314.
20. Carbone PP, Kaplan HS, Musshoff K. Smithers DW, Tubiana, M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
22. Kaplan E, Meier P. Non parametric exstimation for incomplete observation. J Am Stat Assoc. 1958;53:457-481.
23. Lorand-Metze I, Oliveira GB, Aranha FJ. Treatment of prolymphocytic leukemia with cladribine. Ann Hematol. 1998;76:85-86.
24. Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies-a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol. 1999;10:1493-1498.
25. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999;17:3117-3121.
26. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol. 2003;120:970-977.
27. Aviles A, Neri N, Huerta-Guzman J, Fernandez R. Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology. 2004;66:197-200.
28. Emmanouilides C, Colovos C, Pinter-Brown L, et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004;5:45-49.